Researchers at Mount Sinai have developed a unique algorithm that can rapidly detect COVID-19 based on how lung disease looks in computed tomography (CT scans) of the chest, in combination with patient information including symptoms, age, bloodwork, and possible contact with someone infected with the virus.
Combination of Genentech’s Actemra, Gilead’s Remdesivir Enters Phase III Trial for Treatment of Severe...
The global randomized, double-blind, placebo-controlled Phase III trial—to be called REMDACTA—will compare the safety and efficacy of Actemra plus remdesivir to placebo plus remdesivir in severe COVID-19 patients receiving standard of care.
The guidelines—based on published and preliminary data—are posted online at covid19treatmentguidelines.nih.gov and will be updated regularly as new data from peer-reviewed scientific literature and other authoritative information emerges.
The study defined recovery as being discharged from the hospital or being medically stable enough to be discharged from the hospital. The median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo
COVID-19 infects cells by binding to the ACE2 protein, found on the surface of cells in the lungs, cardiovascular system, kidneys, and in the gut. The research says the biggest predictor of high ACE2 levels is being male.
The NIAID-sponsored clinical trial is a large randomized, controlled clinical trial to determine whether hydroxychloroquine, given in combination with the antibiotic azithromycin, can prevent hospitalization and death due to COVID-19.
The researchers demonstrated that ketone bodies, which are molecular byproducts that gives the ketogenic diet its name, directly change levels of certain types of gut bacteria, which led to reduced levels of intestinal pro-inflammatory immune cells.
Delivered as a comprehensive Software-As-A-Service (SaaS) solution, the LabVantage COVID-19 Biobanking Accelerator requires no infrastructure investment.
Antibody testing will help provide a greater understanding of the virus, including how long antibodies stay in the body and how much of the population has been infected.
Smoking increases the gene expression of ACE2—the protein that binds SARS-CoV-2. The study suggests that prolonged smoking could cause an increase of the ACE2 protein in the lungs, possibly resulting in a higher rate of morbidity in patients.